167 related articles for article (PubMed ID: 37400539)
1. Dissolution of oncofusion transcription factor condensates for cancer therapy.
Wang Y; Yu C; Pei G; Jia W; Li T; Li P
Nat Chem Biol; 2023 Oct; 19(10):1223-1234. PubMed ID: 37400539
[TBL] [Abstract][Full Text] [Related]
2. Dissolving Fusion Oncoprotein Condensates to Reverse Aberrant Gene Expression.
Shirnekhi HK; Chandra B; Kriwacki RW
Cancer Res; 2023 Oct; 83(20):3324-3326. PubMed ID: 37828859
[TBL] [Abstract][Full Text] [Related]
3. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
[TBL] [Abstract][Full Text] [Related]
4. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
5. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
6. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma.
Showpnil IA; Selich-Anderson J; Taslim C; Boone MA; Crow JC; Theisen ER; Lessnick SL
Nucleic Acids Res; 2022 Sep; 50(17):9814-9837. PubMed ID: 36124657
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
8. A Druggable Rheostat for Ewing Sarcoma?
Weiss KR; Bailey KM
Clin Cancer Res; 2022 Oct; 28(20):4360-4362. PubMed ID: 35921177
[TBL] [Abstract][Full Text] [Related]
9. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
10. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
[TBL] [Abstract][Full Text] [Related]
11. RUNX3 facilitates growth of Ewing sarcoma cells.
Bledsoe KL; McGee-Lawrence ME; Camilleri ET; Wang X; Riester SM; van Wijnen AJ; Oliveira AM; Westendorf JJ
J Cell Physiol; 2014 Dec; 229(12):2049-56. PubMed ID: 24812032
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
[TBL] [Abstract][Full Text] [Related]
13. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
14. Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles.
Tsugita M; Yamada N; Noguchi S; Yamada K; Moritake H; Shimizu K; Akao Y; Ohno T
PLoS One; 2013; 8(10):e77416. PubMed ID: 24124617
[TBL] [Abstract][Full Text] [Related]
15. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1.
Deng Q; Natesan R; Cidre-Aranaz F; Arif S; Liu Y; Rasool RU; Wang P; Mitchell-Velasquez E; Das CK; Vinca E; Cramer Z; Grohar PJ; Chou M; Kumar-Sinha C; Weber K; Eisinger-Mathason TSK; Grillet N; Grünewald TGP; Asangani IA
Cell Rep; 2022 Jun; 39(11):110971. PubMed ID: 35705030
[TBL] [Abstract][Full Text] [Related]
16. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
[TBL] [Abstract][Full Text] [Related]
18. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.
Bilke S; Schwentner R; Yang F; Kauer M; Jug G; Walker RL; Davis S; Zhu YJ; Pineda M; Meltzer PS; Kovar H
Genome Res; 2013 Nov; 23(11):1797-809. PubMed ID: 23940108
[TBL] [Abstract][Full Text] [Related]
20. Cruel fusion: What a young man's death means for childhood cancer.
Ledford H
Nature; 2017 Mar; 543(7647):608-611. PubMed ID: 28358102
[No Abstract] [Full Text] [Related]
[Next] [New Search]
